Which medications in the drug class Melatonin Receptor Agonists are used in the treatment of Sleep-Wake Disorders?

Updated: Aug 21, 2019
  • Author: Roy H Lubit, MD, PhD; Chief Editor: Ana Hategan, MD, FRCPC  more...
  • Print
Answer

Melatonin Receptor Agonists

Melatonin receptor agonists (tasimelteon, ramelteon) have been approved by the FDA. Tasimelteon is indicated for non–24-hour sleep-wake disorder. Ramelteon is indicated for insomnia characterized by difficulty with sleep onset.

Tasimelteon (Hetlioz)

Tasimelteon is a melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus of the brain. MT1 and MT2 are thought to synchronize the body's melatonin and cortisol circadian rhythms with the day-night cycle in patients with non–24-hour disorder. It is indicated for non–24-hour sleep-wake disorder in the totally blind.

Ramelteon (Rozerem)

Ramelteon is a melatonin receptor agonist with high selectivity for human melatonin MT1 and MT2 receptors. MT1 and MT2 are thought to promote sleep and to be involved in maintenance of circadian rhythm and normal sleep-wake cycles. Ramelteon is indicated for insomnia characterized by difficulty with sleep onset.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!